Willow semaglutide refers to semaglutide prescribed through Willow Health, a telehealth platform that connects patients with licensed clinicians for weight-management evaluation. Willow is one of dozens of similar services that surged during the 2022–2024 GLP-1 boom. This article covers how the telehealth model works, what semaglutide does, safety considerations with compounded versus brand products, and questions to ask before signing up. This is informational only — eligibility and dosing decisions belong with a licensed clinician.
How Telehealth Semaglutide Works
Services like Willow Health follow a common template:
- Create an account and complete a health questionnaire (BMI, medical history, medications, labs).
- Submit photo ID and sometimes recent lab results.
- A licensed clinician reviews the intake asynchronously or via video visit.
- If appropriate, a prescription is sent to a partner pharmacy.
- Medication ships to your door, typically in a pre-drawn syringe or vial plus syringes.
- Ongoing monthly refills with periodic check-ins.
Some platforms prescribe brand semaglutide (Wegovy, Ozempic, Rybelsus); most, historically, have relied on compounded semaglutide because brand prices and shortages limited access.
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics glucagon-like peptide-1, a gut hormone released after eating. Effects include:
- Stimulating glucose-dependent insulin release
- Suppressing glucagon secretion
- Slowing gastric emptying
- Reducing appetite via receptors in the brain
FDA-approved brand semaglutide products:
- Ozempic — weekly injection for type 2 diabetes
- Wegovy — weekly injection for chronic weight management (approved 2021)
- Rybelsus — daily oral tablet for type 2 diabetes
Clinical Results (Brand Data)
The landmark STEP 1 trial (NEJM 2021) tested semaglutide 2.4 mg weekly in 1,961 adults with obesity over 68 weeks:
| Group | Average Weight Change |
|---|---|
| Semaglutide 2.4 mg + lifestyle | −14.9% |
| Placebo + lifestyle | −2.4% |
Subsequent STEP trials confirmed similar results across BMI ranges and with or without type 2 diabetes. Stopping semaglutide typically leads to gradual regain.
Brand vs. Compounded: What to Know
The FDA has flagged meaningful differences:
| Factor | Brand (Wegovy/Ozempic) | Compounded |
|---|---|---|
| FDA approval | Yes | No |
| Manufacturer quality review | Yes | Varies by pharmacy |
| Known safety profile | Extensive | Limited |
| Pen injection | Pre-filled, click-dosed | Often vial + syringe |
| Dosing error risk | Low | Higher |
| Price without insurance | $900–$1,400/month | $150–$400/month |
The FDA has warned specifically about compounded “semaglutide sodium” or “semaglutide acetate” — salt forms not used in FDA-approved products and lacking established safety data.
Shortage Status and the Current Landscape
Brand semaglutide was on the FDA drug shortage list from 2022 through early 2025. Under FDA guidance, compounding pharmacies could legally produce copies of a drug while the active ingredient was in shortage. The semaglutide shortage has since been declared resolved, which restricts large-scale compounding. Some individualized compounding may continue for documented medical need (e.g., allergy to a brand inactive ingredient). Telehealth services are adapting — some are shifting to brand-only prescribing or offering manufacturer direct programs.
Side Effects to Expect
Per NIH MedlinePlus, common and serious effects of semaglutide include:
Common
- Nausea, especially during dose increases
- Diarrhea, constipation, vomiting
- Abdominal pain, bloating
- Decreased appetite
- Fatigue
- Injection-site reactions
Less Common but Serious
- Pancreatitis (severe, persistent abdominal pain)
- Gallbladder disease
- Severe hypoglycemia if combined with insulin or sulfonylureas
- Kidney injury from dehydration
- Allergic reactions
- Vision changes in patients with diabetic retinopathy
Boxed Warning
Semaglutide caused thyroid C-cell tumors in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Questions to Ask Any Telehealth Semaglutide Service
- Is the prescribing clinician licensed in my state?
- Will I be prescribed brand or compounded semaglutide?
- If compounded, is the pharmacy a registered 503A or 503B facility?
- Is the active ingredient semaglutide base, or a non-approved salt form?
- What concentration comes in the vial, and who teaches me to draw the dose?
- What monitoring is included (labs, follow-ups)?
- How do you handle adverse events?
- What is the total monthly cost and cancellation policy?
- Do you accept insurance or offer manufacturer brand pricing?
Who Is Typically Eligible
Most telehealth services evaluate similar criteria to FDA labels for Wegovy:
- BMI 30 or higher (obesity), or
- BMI 27 or higher with a weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
Contraindications include pregnancy, history of medullary thyroid carcinoma, MEN 2, severe gastroparesis, prior pancreatitis, and active eating disorders.
Alternatives to Consider
- Brand Wegovy or Ozempic with insurance coverage or manufacturer savings
- Novo Nordisk’s NovoCare direct-to-consumer offering (as of 2025)
- Tirzepatide (Zepbound) as an alternative GLP-1/GIP medication
- Metformin — cheap, studied, ADA-recommended for prediabetes at higher risk
- Structured lifestyle programs (CDC Diabetes Prevention Program)
Our treatment hub covers the broader medication landscape, and our is prediabetes reversible guide covers the lifestyle foundation that belongs alongside any medication.
The Role of Semaglutide in Prediabetes
Semaglutide is not FDA-approved specifically for prediabetes. However, the ADA notes GLP-1 RAs may be considered in higher-risk adults with prediabetes, especially those with BMI ≥35 or a history of gestational diabetes who have not responded to lifestyle change. First-line treatment remains lifestyle: 5–7% weight loss and 150+ minutes of weekly activity cut progression to type 2 diabetes by 58%.
The Bottom Line
Willow Health and similar telehealth services offer access to semaglutide — sometimes brand, historically often compounded. Semaglutide is an effective, well-studied medication when used as FDA-approved. Compounded versions carry real risks the FDA has flagged, and the regulatory landscape is tightening. Before starting, verify clinician licensing, pharmacy registration, and ingredient sourcing, and weigh alternatives including brand with savings programs. Any medication decision belongs with a licensed clinician who knows your full picture.
This article is educational and not a substitute for personalized medical advice. Always consult your healthcare provider about symptoms, testing, and treatment.
